149,804 Shares in Denali Therapeutics Inc. $DNLI Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 149,804 shares of the company's stock, valued at approximately $3,853,000. Deutsche Bank AG owned about 0.09% of Denali Therapeutics as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. State of Wyoming boosted its stake in shares of Denali Therapeutics by 24.7% during the fourth quarter. State of Wyoming now owns 2,686 shares of the company's stock worth $44,000 after buying an additional 532 shares during the period. Intrust Bank NA grew its holdings in shares of Denali Therapeutics by 5.6% during the fourth quarter. Intrust Bank NA now owns 11,164 shares of the company's stock worth $184,000 after buying an additional 589 shares during the last quarter. ADAR1 Capital Management LLC increased its position in Denali Therapeutics by 1.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company's stock valued at $860,000 after acquiring an additional 600 shares during the period. PNC Financial Services Group Inc. increased its position in Denali Therapeutics by 8.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company's stock valued at $177,000 after acquiring an additional 739 shares during the period. Finally, Pier 88 Investment Partners LLC raised its stake in Denali Therapeutics by 1.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company's stock valued at $1,126,000 after acquiring an additional 760 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.70% of the stock is currently owned by company insiders.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $24.93 on Wednesday. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30. The company has a 50-day moving average price of $24.55 and a 200 day moving average price of $21.64. The company has a market cap of $3.99 billion, a P/E ratio of -8.78 and a beta of 1.01. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter last year, the firm earned ($0.72) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DNLI shares. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a research report on Friday, August 7th. Sanford C. Bernstein restated a "hold" rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Wedbush restated an "outperform" rating and set a $26.00 price target on shares of Denali Therapeutics in a research note on Monday, July 13th. Stifel Nicolaus set a $41.00 price target on Denali Therapeutics in a report on Monday, June 22nd. Finally, Wall Street Zen upgraded shares of Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $35.85.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source